Status:
COMPLETED
Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Conditions:
Chemotherapy-induced Neutropenia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Determination of the effect of balugrastim on the duration and severity of severe neutropenia.
Eligibility Criteria
Inclusion
- Breast cancer participants scheduled to receive the AT regimen (doxorubicin/ docetaxel).
Exclusion
- Participants may have received no more than 1 prior chemotherapy regimen (including adjuvant therapy if given within the last 12 months).
Key Trial Info
Start Date :
August 21 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 26 2009
Estimated Enrollment :
334 Patients enrolled
Trial Details
Trial ID
NCT00837265
Start Date
August 21 2008
End Date
June 26 2009
Last Update
April 3 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.